Brand name: Doxil®
Liposomal doxorubicin is a chemotherapy drug that interferes with cancer cells’ production of DNA, the genetic material of the cell. By doing this, liposomal doxorubicin impairs the ability of cancer cells to keep growing. The drug has been used by itself and with other drugs in the treatment of many kinds of cancer including cutaneous T-cell lymphoma (CTCL). Liposomal doxorubicin is a special formulation of doxorubicin.
Liposomal doxorubicin is given intravenously.
Treatment with liposomal doxorubicin alone, or with other treatments, can improve symptoms of skin lymphoma and reduce skin lesions. Liposomal doxorubicin does not work in all patients. It is important to discuss with your physician whether this might be an appropriate therapy and what the expected results might be for your individual disease.
Liposomal doxorubicin is chemotherapy.
The following is not an exhaustive list of the possible side effects. For a complete list of possible side effects, please see the manufacturer’s available information on the specific therapy.
Liposomal doxorubicin, like other chemotherapy drugs, can cause temporary decreases in blood counts that might increase the risk for infections.